Universal Influenza Vaccine Candidate Competes Phase 1 Dosing
New York-based Codagenix Inc. announced today that it had completed the dosing of its Phase 1 clinical trial to evaluate CodaVax™-H1N1, a universal, live-attenuated, cell-based influenza vaccine candidate.
The randomized, double-blind clinical trial is being conducted in Australia and aims to assess the vaccine's safety, tolerability, and immunogenicity in healthy adults 18-49 years of age.
Study participants will be enrolled in autumn 2022 (southern hemisphere) and followed through the 2022 influenza season.
Initial results from this study are anticipated in Q4 2022.
While existing influenza vaccines must be reformulated each year, CodaVax-H1N1 is a universal influenza vaccine designed to induce protection against all strains of influenza by safely leveraging the unique and proven benefits of live-attenuated vaccines induce strong cellular immunity and durable antibody responses.
J. Robert Coleman, Ph.D., Co-founder, and CEO of Codagenix, commented in a press release issued on June 14, 2022, "CodaVax-H1N1 is well-suited for cost-effective manufacturing at commercial scales, ensuring it is readily available and accessible for global distribution."
Pre-clinical data have demonstrated the potential of CodaVax-H1N1 to induce an antibody response to stalk antigens from a divergent high-path H5 strain in non-human primates.
CodaVax-H1N1 is produced via cell-based manufacturing, which is amenable to rapid scale-up.
For more information, visit codagenix.com.
Additional influenza vaccine breaking news is posted at PrecisionVaccinations.com/Flu.
Note: This announcement was manually curated for mobile readers.